Bicycle Therapeutics (NASDAQ:BCYC) has released updated Phase 1/2 clinical results for its promising oncology treatments at the European Society for Medical Oncology (ESMO) Congress 2024.
The data showcased positive responses from several investigational therapies, including zelenectide pevedotin (formerly BT8009) for metastatic urothelial cancer (mUC), BT5528 for advanced solid tumors, and BT7480 for Nectin-4-associated tumors.
"We are pleased that the data presented at ESMO continue to support the promising response and differentiated safety profiles of our Bicycle molecules," said Kevin Lee, CEO of Bicycle Therapeutics.
The company remains optimistic about its technology's potential, aiming to "create differentiated medicines designed to help patients not only to live longer but also to live well," added Lee.